ArticleCureus2025
Cervical Adenocarcinoma in the Shadows: The Impact of Missed Screening.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical adenocarcinoma is a rising concern in women's health, particularly due to its increasing incidence among younger women and its ability to evade early detection through conventional cytology-based screening. Unlike squamous cell carcinoma, adenocarcinoma often arises higher in the endocervical canal, making it more challenging to detect, especially in patients who default on cervical screening. We report the case of a 39-year-old British lady who presented with severe anemia secondary to heavy vaginal bleeding. She had never attended cervical screening despite living in a country with an established national screening program. Clinical examination revealed a friable cervical mass. Initial investigations revealed profound microcytic hypochromic anemia requiring urgent transfusion. Imaging with CT demonstrated a bulky, irregular cervix with suspicious pelvic lymphadenopathy, while MRI confirmed a large cervical mass (7.4 × 6.5 × 6.0 cm) with parametrial extension and para-aortic nodal disease, consistent with International Federation of Gynecology and Obstetrics (FIGO) Staging stage IIIC2 cervical carcinoma. Histopathology revealed Human Papillomavirus (HPV)-associated adenocarcinoma, Silva pattern C, with strong carcinoembryonic antigen (CEA) positivity and no lymphovascular invasion. Following multidisciplinary team review, the patient was referred for definitive chemoradiotherapy. This case illustrates how defaulted cervical screening can result in delayed diagnosis and advanced disease, even within high-resource healthcare systems. It highlights the diagnostic challenges specific to adenocarcinoma, the limitations of Pap smear in detecting glandular lesions, and the importance of HPV-based screening and public education to improve participation. Early recognition of abnormal bleeding and systematic evaluation with MRI and histopathology are crucial for timely diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.